skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed  dyslipidemias and primary hypercholesterolemia

Review

(2263) Views  (623) Full article downloads

Authors: Adie Viljoen, Anthony S Wierzbicki

Published Date May 2010 Volume 2010:2 Pages 61 - 71
DOI: http://dx.doi.org/10.2147/DHPS.S7302

Adie Viljoen1, Anthony S Wierzbicki2

1Lister Hospital, Stevenage, Hertfordshire, UK; 2Guy’s and St Thomas Hospitals, London, UK

Abstract: Statins form the cornerstone of pharmaceutical cardiovascular disease prevention. However, despite very effective statin intervention, the majority of events remain unpreventable. In some cases statin therapy alone is insufficient to achieve adequate lipid levels whereas other patients are unable to tolerate statins. This calls for additional treatment options. Niacin has a long history of success in reducing low-density lipoprotein cholesterol and triglycerides, and increasing high-density lipoprotein cholesterol. It was the first lipid-lowering drug to demonstrate a reduction in cardiovascular events, and remains the only one that has consistently shown benefits on surrogate outcomes when added to background therapies of other lipid-lowering drugs, including statins. Niacin’s uptake in clinical practice has been less successful due to its side-effect profile, most notable being flushing. The uncovering of the mechanism by which flushing is induced, together with the development of a prostaglandin D2 receptor inhibitor (laropiprant) which reduces this downstream flushing effect of niacin, has sparked new promise in therapeutic lipid management. It provides an additional treatment option into managing lipid abnormalities. The uptake in clinical practice of the niacin–laropiprant combination will depend on the relative improvements experienced by the patient in the side-effect profile compared to other treatment options, as well as on the the keenly-awaited outcome studies currently underway. Until these data become available guidelines and recommendations are unlikely to change and niacin’s position in therapeutic cardiovascular risk prevention will be determined by clinician opinion and experience, and patient preferences.

Keywords: niacin, laropiprant, lipid abnormalities






 

Other articles by Dr Adie Viljoen



Readers of this article also read:

Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Erratum - Intracellular heavy metal nanoparticle storage
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Primary care for diabetes mellitus: perspective from older patients
Erratum
Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio